Infanrix hexa™

BIOLOGICAL9 trials

Sponsors

Sanofi Pasteur, a Sanofi Company, GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b VaccinesDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniHaemophilus Influenzae Type B InfectionHaemophilus Influenzae Type bHepatitis BInfections, Rotavirus

Phase 2

Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

CompletedNCT00970307

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni +4

Start: 2009-08-13End: 2010-01-27Updated: 2020-01-03

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

CompletedNCT01090453

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +4

Start: 2010-05-17End: 2011-10-11Updated: 2018-08-20

Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine

WithdrawnNCT01110044

GlaxoSmithKlineInfections, Rotavirus

Start: 2010-04-30End: 2012-08-31Updated: 2015-03-27

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

CompletedNCT01171989

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni +4

Start: 2010-08-18End: 2010-12-03Updated: 2020-01-21

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

CompletedNCT01248884

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +3

Start: 2010-12-09End: 2012-01-05Updated: 2018-08-20

Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

CompletedNCT01616459

GlaxoSmithKlineInfections, Streptococcal

Start: 2012-07-11End: 2014-01-22Updated: 2019-07-16

Phase 3

Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™

CompletedNCT00654901

Sanofi Pasteur, a Sanofi CompanyDiphtheria, Haemophilus Influenzae Type B Infection, Hepatitis B +3

Start: 2008-03-31End: 2009-07-31Updated: 2016-05-13

Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam

CompletedNCT01153841

GlaxoSmithKlineInfections, Streptococcal, Streptococcus Pneumoniae Vaccines

Start: 2011-02-17End: 2011-07-26Updated: 2020-01-02

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

CompletedNCT01353703

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines +4

Start: 2012-04-16End: 2013-02-25Updated: 2020-01-02

Related Papers

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and<i>Haemophilus influenzae</i>type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed<i>Infanrix hexa</i>

Human Vaccines & Immunotherapeutics2017-03-241 citations

A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age.

2014-12-014 citations

A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.

2013-07-016 citations